Avoro Capital Advisors LLC Has $34.60 Million Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Avoro Capital Advisors LLC lifted its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 7.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,999,999 shares of the company's stock after purchasing an additional 1,349,999 shares during the period. Taysha Gene Therapies comprises 0.5% of Avoro Capital Advisors LLC's holdings, making the stock its 28th biggest holding. Avoro Capital Advisors LLC owned about 9.76% of Taysha Gene Therapies worth $34,600,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in TSHA. Charles Schwab Investment Management Inc. increased its holdings in shares of Taysha Gene Therapies by 2.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock valued at $820,000 after buying an additional 11,390 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Taysha Gene Therapies by 23.7% during the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company's stock worth $7,163,000 after purchasing an additional 682,273 shares during the period. Barclays PLC boosted its position in shares of Taysha Gene Therapies by 356.0% in the 3rd quarter. Barclays PLC now owns 247,280 shares of the company's stock valued at $513,000 after purchasing an additional 193,046 shares during the period. State Street Corp boosted its position in shares of Taysha Gene Therapies by 4.5% in the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company's stock valued at $6,973,000 after purchasing an additional 150,647 shares during the period. Finally, Vanguard Group Inc. increased its stake in Taysha Gene Therapies by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company's stock worth $15,409,000 after purchasing an additional 641,305 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on TSHA shares. Chardan Capital reissued a "buy" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a "buy" rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, April 10th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of "Buy" and an average price target of $6.63.

Taysha Gene Therapies Stock Down 3.3 %

TSHA stock traded down $0.06 during mid-day trading on Friday, hitting $1.76. The stock had a trading volume of 1,698,834 shares, compared to its average volume of 2,704,175. The stock has a market capitalization of $360.90 million, a price-to-earnings ratio of 2.79 and a beta of 0.96. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies, Inc. has a 1-year low of $1.05 and a 1-year high of $4.32. The company has a fifty day moving average of $1.55 and a 200 day moving average of $1.80.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. The firm had revenue of $2.02 million for the quarter, compared to analyst estimates of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. On average, equities analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.